Even as the Nasdaq Composite is surging to new highs, investors can still find stocks within the index that have room to run.
These stocks have a consensus buy rating from analysts and have an upside of 20% or more from their average price targets.
Analysts have a consensus buy rating on both stocks, and think AstraZeneca could rally more than 26%, while Biogen could jump roughly 40%.
Bank of America last month reiterated its buy rating on Baker Hughes.
Twenty-two of the 27 analysts polled by LSEG rate the stock a buy or strong buy, and the average price target suggests 35% upside from here.
Persons:
Biogen, Wells, Baker Hughes, Saurabh Pant
Organizations:
Nasdaq, CNBC, Stock, AstraZeneca, Warner Bros, Biotechnology, Biogen, Deutsche Bank, Analysts, Moderna, HSBC, Discovery, Bank of America, CCS, " Bank of America